Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Successful TAVR of a native aortic valve stenosis~* By iliofemoral or subclavian access~* With any approved/marketed TAVR device~* Written informed consent~Exclusion Criteria:~* Atrial fibrillation (AF), current or previous, with an ongoing indication for oral anticoagulant treatment~* Any other indication for continued treatment with any oral anticoagulant~* Known bleeding diathesis (such as but not limited to platelet count ≤ 50,000/mm3 at screening, hemoglobin level \< 8.5 g/dL or \< 5.3 mmol/l, history of intracranial hemorrhage, or subdural hematoma)~* Any indication for dual antiplatelet therapy (DAPT) for more than three months after randomization (such as coronary, carotid, or peripheral stent implantation)~* Clinically overt stroke within the last three months~* Planned coronary or vascular intervention or major surgery~* Severe renal insufficiency (eGFR \< 30 mL/min/1.73 m2) or on dialysis, or post-TAVR unresolved acute kidney injury with renal dysfunction ≥ stage 2~* Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy~* Iodine contrast allergy or other condition that prohibits CT imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASA + Clopidogrel (Type: ACTIVE_COMPARATOR): ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
- Rivaroxaban + ASA (Type: EXPERIMENTAL): Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).